Radiation beads plus immunotherapy: a new hope for advanced liver cancer?
NCT ID NCT05377034
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding two drugs (atezolizumab and bevacizumab) after a targeted radiation treatment (SIRT-Y90) can help shrink tumors in people with advanced liver cancer that hasn't spread. About 100 participants will be randomly assigned to receive either the drug combination or a placebo after radiation. The main goal is to see how many patients have their tumors shrink or disappear within 9 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Y-90 resin microspheres (radiation beads) followed by atezolizumab plus bevacizumab (immunotherapy and anti-angiogenic drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer that hasn't spread outside the liver, potentially shrinking tumors and improving outcomes.
What could go wrong
This is a phase 2 trial with only 100 participants, so results are preliminary. The added drugs may cause side effects like fatigue, high blood pressure, or immune reactions, and the combination may not work better than radiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
RECRUITINGBeijing, China
-
Kaohsiung Chang Gung Memorial Hospital
RECRUITINGKaohsiung City, Taiwan
-
National Cancer Centre Singapore
RECRUITINGSingapore, 168583, Singapore
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Taiwan University Cancer Center
RECRUITINGTaipei, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
-
National University Hospital
RECRUITINGSingapore, 119074, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
People's Liberation Army General Hospital (1st and 6th Medical Centre)
NOT_YET_RECRUITINGBeijing, China
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
-
Severance Hospital Yonsei University Health System
RECRUITINGSeoul, South Korea
-
Shandong Cancer Hospital
NOT_YET_RECRUITINGJinan, China
-
Taichung Veterans General Hospital
RECRUITINGTaichung, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan
-
West China Hospital, Sichuan University
RECRUITINGChengdu, China